PET/CT

Miniaturized Platform for PET Radiotracer Production

USC researchers are developing a miniaturized PET radiotracer platform designed to simplify production, accelerate tracer development and expand molecular imaging applications.

Bayer Reports Phase III PET Radiotracer Results in Cardiac Amyloidosis

Bayer reports Phase III results for investigational I 124 evuzamitide in cardiac amyloidosis, with primary endpoints met for visual PET scan interpretation.

Philips Receives FDA Clearance for Rembra CT Platform

Philips has received FDA 510(k) clearance for its Rembra imaging platform, including Rembra CT, Rembra RT and Areta RT, designed to support high-throughput CT imaging and radiation therapy planning across the cancer care pathway.

Bayer PET Tracer Hits Phase III Goals in Cardiac Amyloidosis

Phase III data support Bayer’s PET tracer for non-invasive cardiac amyloidosis diagnosis.

Catalyst MedTech Expands Brain PET Implementation in the U.S.

The solution is designed to enable healthcare providers to implement molecular imaging workflows without traditional infrastructure barriers.

Clatterbridge Installs PET-CT System to Cut Scan Times

The Clatterbridge Cancer Centre has installed the UK’s first Biograph Trinion PET-CT system, increasing imaging capacity.

Bayer Expands Radiology Portfolio Into Diagnostic Tracers

Acquisition of AT-01 and AT-05 expands Bayer’s molecular imaging portfolio.

RSNA 2025: Imaging the Hidden Language of the Brain

A session highlighting how amyloid, tau, and FDG PET sharpen Alzheimer’s diagnosis, support therapy decisions, and improve safety monitoring, marking a key advance in precision imaging.

RSNA Insights: Imaging’s Evolving Role in Ovarian Cancer Care

RSNA 2025 session insights show how precision imaging is reshaping ovarian cancer care and patient survival.